Compare Citius Pharmaceuticals Inc (CTXR) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Smith & Nephew plc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Smith & Nephew plc trades at $30.97 (market cap $12.40B). The key difference: Smith & Nephew plc is far larger — about 847× Citius Pharmaceuticals Inc's market cap, and Smith & Nephew plc pays a 2.62% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | SNN | |
|---|---|---|
Market Cap | $14.64M | $12.40B |
Sector | Health | Health |
52-Week High | $1.82 | $38.70 |
52-Week Low | $0.53 | $28.73 |
Enterprise Value | $10.86M | $15.17B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
SNN trades at $31.08, up 1.24% with a bullish technical signal. The company shows improving fundamentals with 2024 revenue of $5.81B and net income of $412M, while recent earnings beat expectations. Strong cash flow generation and new product launches in robotics and wound care support growth. Analyst consensus is mixed with 27% buy ratings but majority holds.
Outlook remains positive with projected revenue growth and margin expansion, though recent earnings misses and elevated valuation metrics pose risks. The stock's technical strength and fundamental recovery present opportunity, but investor caution is warranted given mixed analyst sentiment and competitive pressures in medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
